TRIN News & Events

Emboline announced it has closed $20M in growth capital from Trinity Capital, a leading international alternative asset manager. Emboline recently completed enrollment in the PROTECT H2H investigational device exemption, or IDE, clinical trial, a prospective randomized study evaluating the Emboliner Embolic Protection System. The funding will support Emboline's upcoming commercial launch activities and continued development of its embolic protection technology platform.The Emboliner Embolic Protection System is designed to provide full cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures. Emboline also holds an extensive intellectual property portfolio related to aortic embolic protection technologies, including full-body embolic filtration and aortic deflection approaches. Results from the completed IDE clinical study will be presented in a Late-Breaking Clinical Trial session on March 29 at the American College of Cardiology Annual Scientific Session in New Orleans, Louisiana. With this financing, Emboline will advance preparations for the commercial introduction of the Emboliner Embolic Protection System while continuing development of additional technologies designed to reduce embolic risk during structural heart interventions.

Trinity Capital announced the commitment of $35M in growth capital to Neuros Medical, a MedTech company focused on alleviating chronic post-amputation pain and restoring quality of life through neuromodulation technologies. This new capital will help Neuros Medical scale the commercialization of the Altius system and expand into new markets.

Reports Q4 revenue $83.2M, consensus $80.01M . Reports Q4 NAV of $1.1B, or $13.42 per share. NAV increased 32.9% year-over-year. Reports Q4 15.3% ROAE. "Trinity Capital had a milestone year in 2025, including record originations, earnings growth, and continued diversification across our five lending verticals," CEO Kyle Brown said. "These results directly reflect the consistency of our disciplined underwriting approach and the scalability of our platform as a whole." Added Brown: "Our internally managed structure remains a key differentiator. By aligning management and shareholder interests within a single platform, and pairing our publicly traded BDC with a growing managed funds business, we're building a robust and flexible capitalization model designed to support long-term growth and deliver stable, consistent returns for shareholders. With more than six years of consistent dividends and continued momentum across our portfolio, we remain focused on disciplined execution and delivering long-term value for our investors, partners, and shareholders."